Patents by Inventor David E. Gunn

David E. Gunn has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20120270878
    Abstract: This invention relates to the use of a group of aryl ureas in treating cytokine mediated diseases and proteolytic enzyme mediated diseases, and pharmaceutical compositions for use in such therapy.
    Type: Application
    Filed: July 2, 2012
    Publication date: October 25, 2012
    Applicant: BAYER HEALTHERCARE LLC
    Inventors: Scott MILLER, Martin OSTERHOUT, Jacques DUMAS, Uday KHIRE, Timothy B. LOWINGER, William J. SCOTT, Roger A. SMITH, Jill E. WOOD, David E. GUNN, Holia HATOUM-MOKDAD, Marell RODRIGUEZ, Robert SIBLEY, Ming WANG, Tiffany TURNER, Catherine BRENNAN
  • Patent number: 7928239
    Abstract: This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions in such therapy.
    Type: Grant
    Filed: February 7, 2001
    Date of Patent: April 19, 2011
    Assignee: Bayer Healthcare LLC
    Inventors: Jacques Dumas, Bernd Riedl, Uday Khire, Jill E. Wood, Robert N. Sibley, Mary-Katherine Monahan, Joel Renick, David E. Gunn, Timothy B. Lowinger, William J. Scott, Roger A. Smith
  • Patent number: 7517880
    Abstract: This invention relates to the use of a group of aryl ureas in treating cytokine mediated diseases and proteolytic enzyme mediated diseases, and pharmaceutical compositions for use in such therapy.
    Type: Grant
    Filed: February 1, 2002
    Date of Patent: April 14, 2009
    Assignee: Bayer Pharmaceuticals Corporation
    Inventors: Scott Miller, Martin Osterhout, Jacques Dumas, Uday Khire, Timothy B. Lowinger, William J. Scott, Roger A. Smith, Jill E. Wood, David E. Gunn, Holia Hatoum-Mokdad, Marell Rodriguez, Robert Sibley, Ming Wang, Tiffany Turner, Catherine Brennan
  • Publication number: 20090093526
    Abstract: This invention relates to the use of a group of aryl ureas in treating cytokine mediated diseases and proteolytic enzyme mediated diseases, and pharmaceutical compositions for use in such therapy.
    Type: Application
    Filed: October 31, 2007
    Publication date: April 9, 2009
    Inventors: Scott Miller, Martin Osterhout, Jacques Dumas, Uday Khire, Timothy B. Lowinger, William J. Scott, Roger A. Smith, Jill E. Wood, David E. Gunn, Holia Hatoum-Mokdad, Marell Rodriguez, Robert Sibley, Ming Wang, Tiffany Turner, Catherine Brennan
  • Publication number: 20080194580
    Abstract: This invention relates to a group of quinolyl, isoquinolyl and pyridyl ureas, their the use in treating raf mediated diseases, and pharmaceutical compositions which contain these ureas for use in such therapy.
    Type: Application
    Filed: October 31, 2007
    Publication date: August 14, 2008
    Inventors: Jacques Dumas, Bernd Riedl, Uday Khire, Robert N. Sibley, Holia Hatoum-Mokdad, Mary-Katherine Monahan, David E. Gunn, Timotthy B. Lowinger, William J. Scott, Roger A. Smith, Jill E. Wood
  • Patent number: 7371763
    Abstract: The invention relates to a group of quinolyl, isoquinolyl and pyridyl ureas, their the use in treating raf mediated diseases, and pharmaceutical compositions which contain these ureas for use in such therapy.
    Type: Grant
    Filed: June 22, 2005
    Date of Patent: May 13, 2008
    Assignee: Bayer Pharmaceuticals Corporation
    Inventors: Jacques Dumas, Bernd Riedl, Uday Khire, Robert N. Sibley, Holia Hatoum-Mokdad, Mary-Katherine Monahan, David E. Gunn, Timotthy B. Lowinger, William J. Scott, Roger A. Smith, Jill E. Wood
  • Patent number: 7109196
    Abstract: The invention relates generally to naphthyridine derivatives of the formula wherein one of U, X, Y and Z is nitrogen and the others are C—R, where R is hydrogen or a substituent. More specifically, the invention relates to 1,8-naphthyridine derivatives and pharmaceutical compositions containing such derivatives. Methods of the invention comprise administration of a naphthyridine derivative of the invention for the treatment of diabetes and related disorders.
    Type: Grant
    Filed: April 28, 2004
    Date of Patent: September 19, 2006
    Assignee: Bayer Pharmaceuticals Corporation
    Inventors: Yamin Wang, William H. Bullock, David E. Gunn, Qingjie Liu, Sidney X. Liang, Donglei Liu, Steven R. Magnuson, Tindy Li, Eric S. Mull, Jill E. Wood, Ning Qi
  • Patent number: 6900205
    Abstract: The invention relates generally to naphthyridine derivatives of the formula wherein one of U, X, Y and Z is nitrogen and the others are C—R, where R is hydrogen or a substituent. More specifically, the invention relates to 1,8-naphthyridine derivatives and pharmaceutical compositions containing such derivatives. Methods of the invention comprise administration of a naphthyridine derivative of the invention for the treatment of diabetes and related disorders.
    Type: Grant
    Filed: September 23, 2002
    Date of Patent: May 31, 2005
    Assignee: Bayer Pharmaceuticals Corporation
    Inventors: Yamin Wang, William H. Bullock, David E. Gunn, Qingjie Liu, Sidney X. Liang, Donglei Liu, Steven R. Magnuson, Tindy Li, Eric S. Mull, Jill E. Wood, Ning Qi
  • Publication number: 20040209866
    Abstract: The invention relates generally to naphthyridine derivatives of the formula 1
    Type: Application
    Filed: April 28, 2004
    Publication date: October 21, 2004
    Applicant: Bayer Pharmaceuticals Corporation
    Inventors: Yamin Wang, William H. Bullock, David E. Gunn, Qingjie Liu, Sideny X. Liang, Donglei Liu, Steven R. Magnuson, Tindy Li, Eric S. Mull, Jill E. Wood, Ning Qi
  • Patent number: 6784167
    Abstract: 17-beta-hydroxysteroid dehydrogenase-II inhibitors having the structural formula wherein the phenyl group labeled A and the group —C(R4)(R6)Y are oriented cis to each other; W represents O or S; R1 represents —H or optionally substituted —(C1-C4)alkyl; n represents 0 or an integer of 1-3; and R2 represents any of a variety of substituents on ring A. R4 generally represents —H but may be a bond terminating at the ortho position of ring A. Y represents fluorine, —OR5, or —SR5, and R5 represents —H, optionally substituted —(C1-C4)alkyl, optionally substituted -phenyl, optionally substituted —(C1-C4)alkyl-phenyl, or optionally substituted —(C1-C4)acyl. R6 represents any of a variety of groups as defined in the specification and claims, including heteroaryl, arylalkyl, heteroarylalkyl, arylalkenyl, heteroarylalkenyl, alkynyl, arylalkynyl, heteroarylalkynyl, aryl, and indolyl.
    Type: Grant
    Filed: September 28, 2001
    Date of Patent: August 31, 2004
    Assignee: Bayer Pharmaceuticals Corporation
    Inventors: Jill E. Wood, Jeremy L. Baryza, Catherine R. Brennan, Soongyu Choi, James H. Cook, Brian R. Dixon, Paul P. Ehrlich, David E. Gunn, Ian McAlexander, Peiying Liu, Derek B. Lowe, Anikó M. Redman, William J. Scott, Yamin Wang
  • Publication number: 20040102636
    Abstract: This invention relates to the use of a group of aryl ureas in treating cytokine mediated diseases and proteolytic enzyme mediated diseases, and pharmaceutical compositions for use in such therapy.
    Type: Application
    Filed: February 1, 2002
    Publication date: May 27, 2004
    Applicant: BAYER CORPORATION
    Inventors: Scott Miller, Martin Osterhout, Jacques Dumas, Uday Khire, Timothy B. Lowinger, William J. Scott, Roger A. Smith, Jill E. Wood, David E. Gunn, Holia Hatoum-Mokdad, Marell Rodriguez, Robert Sibley, Ming Wang, Tiffany Turner, Catherine Brennan
  • Publication number: 20040014751
    Abstract: The invention relates generally to naphthyridine derivatives of the formula 1
    Type: Application
    Filed: September 23, 2002
    Publication date: January 22, 2004
    Inventors: Yamin Wang, William H. Bullock, David E. Gunn, Qingjie Liu, Sidney X. Liang, Donglei Liu, Steven R. Magnuson, Tindy Li, Eric S. Mull, Jill E. Wood, Ning Qi
  • Publication number: 20030207914
    Abstract: This invention relates to a group of quinolyl, isoquinolyl and pyridyl ureas, their the use in treating raf mediated diseases, and pharmaceutical compositions which contain these ureas for use in such therapy.
    Type: Application
    Filed: April 19, 2002
    Publication date: November 6, 2003
    Applicant: BAYER CORPORATION
    Inventors: Jacques Dumas, Bernd Riedl, Uday Khire, Robert N. Sibley, Holia Hatoum-Mokdad, Mary-Katherine Monahan, David E. Gunn, Timothy B. Lowinger, William J. Scott, Roger A. Smith, Jill E. Wood
  • Publication number: 20030087952
    Abstract: 17-beta-hydroxysteroid dehydrogenase-I1 inhibitors having the structural formula 1
    Type: Application
    Filed: September 28, 2001
    Publication date: May 8, 2003
    Inventors: Jill E. Wood, Jeremy L. Baryza, Catherine R. Brennan, Soongyu Choi, James H. Cook, Brian R. Dixon, Paul P. Ehrlich, David E. Gunn, Ian McAlexander, Peiying Liu, Derek B. Lowe, Aniko M. Redman, William J. Scott, Yamin Wang
  • Publication number: 20020165394
    Abstract: This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions in such therapy.
    Type: Application
    Filed: February 7, 2001
    Publication date: November 7, 2002
    Applicant: BAYER CORPORATION
    Inventors: Jacques Dumas, Bernd Riedl, Uday Khire, Jill E. Wood, Sibley N. Robert, Mary-Katherine Monahan, Joel Renick, David E. Gunn, Timothy B. Lowinger, William J. Scott, Roger A. Smith
  • Publication number: 20020065296
    Abstract: This invention relates to the use of a group of heteroaryl ureas containing nitrogen in treating p38 mediated diseases, and pharmaceutical compositions for use in such therapy.
    Type: Application
    Filed: April 20, 2001
    Publication date: May 30, 2002
    Applicant: BAYER CORPORATION
    Inventors: Jacques Dumas, Bernd Riedl, Uday Khire, Robert N. Sibley, Holia Hatoum-Mokdad, Mary-Katherine Monahan, David E. Gunn, Timotthy B. Lowinger, William J. Scott, Roger A. Smith, Jill E. Wood
  • Patent number: 5948793
    Abstract: Novel heterocyclic ether compounds of the formula: ##STR1## wherein n, *, R.sup.1, R.sup.2, R.sup.3 and y are specifically defined, or pharmaceutically acceptable salts or prodrugs thereof, which are useful in selectively controlling neurotransmitter release; therapeutically-effective pharmaceutical compositions of these compounds; and use of said compositions to selectively control neurotransmitter release in mammals.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: September 7, 1999
    Assignee: Abbott Laboratories
    Inventors: Melwyn A. Abreo, David E. Gunn, Nan-Horng Lin, David S. Garvey, Mark W. Holladay, Keith B. Ryther
  • Patent number: 5914328
    Abstract: Novel heterocyclic ether compounds of the formula: ##STR1## wherein *, A,B, n, R.sup.1, R.sup.2 and X are specifically defined, or pharmaceutically-acceptable salts or prodrugs thereof, which are useful in selectively activating or inhibiting neurotransmitter release; to therapeutically-effective pharmaceutical compositions of these compounds; and to the use of said compositions to activate or inhibit neurotransmitter release in mammals.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: June 22, 1999
    Assignee: Abbott Laboratories
    Inventors: Nan-Horng Lin, Mark W. Holladay, Melwyn A. Abreo, David E. Gunn, Suzanne A. Lebold, Richard L. Elliott, Yun He
  • Patent number: 5843968
    Abstract: Compounds having the formula: ##STR1## wherein W is the same at each occurrence and is selected from optionally substituted quinolyl, optionally substituted benzothiazolyl, optionally substituted benzoxazolyl, optionally substituted benzimidazolyl, optionally substituted quinoxalyl, optionally substituted pyridyl, optionally substituted pyrimidyl, and optionally substituted thiazolyl; R.sup.1 and R.sup.2 are independently selected from hydrogen, alkyl, halolalkyl, alkoxy, halogen; R.sup.3 is a valence bond or is selected from hydrogen and alkyl; X is a valence bond or is selected from alkylene, alkenylen, and alkynylene; and Z is selected from (a) COM, (b) CH.dbd.N--O--A--COM, (c) CH.sub.2 --O--N.dbd.A--COM wherein A is selected from alkylene and cycloalkylene, and M is selected from (a) a pharmaceutically acceptable metabolically cleavable group, (b) --OR.sup.6, (c) --NR.sup.7 R.sup.8, (d) --NR.sup.6 SO.sub.2 R.sup.
    Type: Grant
    Filed: October 27, 1997
    Date of Patent: December 1, 1998
    Assignee: Abbott Laboratories
    Inventors: Clint D. W. Brooks, Pramila Bhatia, Teodozyj Kolasa, Andrew O. Stewart, David E. Gunn, Richard A. Craig
  • Patent number: 5795900
    Abstract: Compounds having the formula: ##STR1## wherein W is the same at each occurrence and is selected from optionally substituted quinolyl, optionally substituted benzothiazolyl, optionally substituted benzoxazolyl, optionally substituted benzimidazolyl, optionally substituted quinoxalyl, optionally substituted pyridyl, optionally substituted pyrimidyl, and optionally substituted thiazolyl; R.sup.1 and R.sup.2 are independently selected from hydrogen, alkyl, halolalkyl, alkoxy, halogen; R.sup.3 is a valence bond or is selected from hydrogen and alkyl; X is a valence bond or is selected from alkylene, alkenylen, and alkynylene; and Z is selected from (a) COM, (b) CH.dbd.N--O--A--COM, (c) CH.sub.2 --O--N.dbd.A--COM wherein A is selected from alkylene and cycloalkylene, and M is selected from (a) a pharmaceutically acceptable metabolically cleavable group, (b) --OR.sup.6, (c) --NR.sup.7 R.sup.8, (d)--NR.sup.6 SO.sub.2 R.sup.
    Type: Grant
    Filed: September 17, 1996
    Date of Patent: August 18, 1998
    Assignee: Abbott Laboratories
    Inventors: Clint D. Brooks, Pramila Bhatia, Teodozyj Kolasa, Andrew O. Stewart, David E. Gunn, Richard A. Craig